{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T11:11:05Z","timestamp":1776424265395,"version":"3.51.2"},"reference-count":38,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Pract Neurol"],"accepted":{"date-parts":[[2018,2,8]]},"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:p>Statins are the Marmite (\u2018You either love it or hate it!\u2019) of the drug world, both in terms of therapeutic benefit and risk of side effects. Proponents think that they are potential life-savers, opponents that their main benefit is lining the pockets of pharma. Some consider side effects to be a major issue, outweighing any therapeutic benefit, others that they are rare and essentially innocuous. Statin-induced myalgia is relatively common but often mild and for most people does not limit treatment. In others, reducing the dose or changing the preparation may help. In all, withdrawal of the statin leads to resolution. Statin-induced rhabdomyolysis, most often precipitated by drug\u2013drug interaction, affects only a tiny proportion of statin users, but because of the widespread prescribing of statins is an important clinical problem. Statin-induced immune-mediated necrotising myopathy represents a novel disease mechanism and clinically mimics forms of myositis. Resolution often requires immunosuppressant drug treatment, as well as statin withdrawal.<\/jats:p>","DOI":"10.1136\/practneurol-2017-001738","type":"journal-article","created":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T20:10:15Z","timestamp":1519935015000},"page":"97-105","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Statin-related myopathies"],"prefix":"10.1136","volume":"18","author":[{"given":"David","family":"Hilton-Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2018,3,1]]},"reference":[{"key":"2025090411012888000_18.2.97.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2014.03.019"},{"key":"2025090411012888000_18.2.97.2","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/ene.12604","article-title":"Statins and the neuromuscular system: a neurologist\u2019s perspective","volume":"22","author":"Argov","year":"2015","journal-title":"Eur J Neurol"},{"key":"2025090411012888000_18.2.97.3","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.136101"},{"key":"2025090411012888000_18.2.97.4","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1016\/S0140-6736(16)31357-5","article-title":"Interpretation of the evidence for the efficacy and safety of statin therapy","volume":"388","author":"Collins","year":"2016","journal-title":"Lancet"},{"key":"2025090411012888000_18.2.97.5","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(17)30718-3","article-title":"Safety and efficacy of statins","volume":"389","author":"Thompson","year":"2017","journal-title":"The Lancet"},{"key":"2025090411012888000_18.2.97.6","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S0140-6736(17)30717-1","article-title":"Safety and efficacy of statins \u2013 Authors' reply","volume":"389","author":"Collins","year":"2017","journal-title":"The Lancet"},{"key":"2025090411012888000_18.2.97.7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.jacl.2016.05.002","article-title":"The nocebo effect in the context of statin intolerance","volume":"10","author":"Tobert","year":"2016","journal-title":"J Clin Lipidol"},{"key":"2025090411012888000_18.2.97.8","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2016-310844"},{"key":"2025090411012888000_18.2.97.9","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jacl.2017.07.003","article-title":"The effects of statins on exercise and physical activity","volume":"11","author":"Noyes","year":"2017","journal-title":"J Clin Lipidol"},{"key":"2025090411012888000_18.2.97.10","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2003.02044.x"},{"key":"2025090411012888000_18.2.97.11","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s11883-010-0134-3","article-title":"Coenzyme Q(10) and statin myalgia: what is the evidence?","volume":"12","author":"Mas","year":"2010","journal-title":"Curr Atheroscler Rep"},{"key":"2025090411012888000_18.2.97.12","doi-asserted-by":"publisher","DOI":"10.4103\/1947-2714.153919"},{"key":"2025090411012888000_18.2.97.13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.4103\/1947-2714.179133","article-title":"Safety of 50,000-100,000 units of vitamin D3\/week in vitamin D-Deficient, hypercholesterolemic patients with reversible statin intolerance","volume":"8","author":"Jetty","year":"2016","journal-title":"N Am J Med Sci"},{"key":"2025090411012888000_18.2.97.14","first-page":"56","article-title":"Impact of vitamin D status on statin-induced myopathy","volume":"6","author":"Riche","year":"2016","journal-title":"J Clin Transl Endocrinol"},{"key":"2025090411012888000_18.2.97.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.02.023"},{"key":"2025090411012888000_18.2.97.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.04.037"},{"key":"2025090411012888000_18.2.97.17","first-page":"42","article-title":"Low plasma vitamin D levels and muscle-related adverse effects in statin users","volume":"16","author":"Eisen","year":"2014","journal-title":"Isr Med Assoc J"},{"key":"2025090411012888000_18.2.97.18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000001268","article-title":"Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies","volume":"94","author":"Hou","year":"2015","journal-title":"Medicine"},{"key":"2025090411012888000_18.2.97.19","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00228-017-2318-z","article-title":"SLCO1B1 521T > C polymorphism associated with rosuvastatin-induced myotoxicity in Chinese coronary artery disease patients: a nested case-control study","volume":"73","author":"Liu","year":"2017","journal-title":"Eur J Clin Pharmacol"},{"key":"2025090411012888000_18.2.97.20","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/mus.25127","article-title":"Absence of anti-HMG-CoA reductase autoantibodies in severe self-limited statin-related myopathy","volume":"54","author":"Floyd","year":"2016","journal-title":"Muscle Nerve"},{"key":"2025090411012888000_18.2.97.21","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000456"},{"key":"2025090411012888000_18.2.97.22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11883-017-0682-x","article-title":"Clinical Guidance for Managing Statin and Antimicrobial Drug-Drug Interactions","volume":"19","author":"Hylton Gravatt","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"2025090411012888000_18.2.97.23","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.09.003"},{"key":"2025090411012888000_18.2.97.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.27572"},{"key":"2025090411012888000_18.2.97.25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/BOR.0000000000000438","article-title":"Immune-mediated necrotizing myopathy associated with statins: history and recent developments","volume":"29","author":"Tiniakou","year":"2017","journal-title":"Curr Opin Rheumatol"},{"key":"2025090411012888000_18.2.97.26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/mus.24637","article-title":"Necrotizing myopathy caused by central hypothyroidism","volume":"52","author":"Tiniakou","year":"2015","journal-title":"Muscle Nerve"},{"key":"2025090411012888000_18.2.97.27","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/RHU.0000000000000497","article-title":"Statin-Associated Autoimmune Myopathy: A Systematic Review of 100 Cases","volume":"23","author":"Nazir","year":"2017","journal-title":"J Clin Rheumatol"},{"key":"2025090411012888000_18.2.97.28","doi-asserted-by":"crossref","unstructured":"Karunaratne K , Amiras D , Pickering MC , et al . Autoimmune necrotising myopathy and HMGCR antibodies. Pract Neurol 2018:practneurol-2017-001848.doi:10.1136\/practneurol-2017-001848","DOI":"10.1136\/practneurol-2017-001848"},{"key":"2025090411012888000_18.2.97.29","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc1506163","article-title":"Intravenous Immune Globulin for Statin-Triggered Autoimmune Myopathy","volume":"373","author":"Mammen","year":"2015","journal-title":"N Engl J Med"},{"key":"2025090411012888000_18.2.97.30","first-page":"787","article-title":"More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutarylcoenzyme A reductase-associated autoimmune myopathy","volume":"56","author":"Tiniakou","year":"2017","journal-title":"Rheumatology"},{"key":"2025090411012888000_18.2.97.31","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB1*11:01 in anti-hydroxymethylglutaryl-coenzyme A reductase-associated autoimmune myopathy","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"2025090411012888000_18.2.97.32","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/aww054"},{"key":"2025090411012888000_18.2.97.33","doi-asserted-by":"publisher","DOI":"10.1002\/art.24037"},{"key":"2025090411012888000_18.2.97.34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.nmd.2016.03.009","article-title":"No relevant excess prevalence of myotonic dystrophy type 2 in patients with suspected fibromyalgia syndrome","volume":"26","author":"van Vliet","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"2025090411012888000_18.2.97.35","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20567"},{"key":"2025090411012888000_18.2.97.36","doi-asserted-by":"publisher","DOI":"10.1159\/000101287"},{"key":"2025090411012888000_18.2.97.37","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2008.09.002"},{"key":"2025090411012888000_18.2.97.38","doi-asserted-by":"crossref","DOI":"10.1002\/mus.25155","article-title":"Statins and Myasthenia Gravis","volume":"54","author":"Khalid","year":"2016","journal-title":"Muscle Nerve"}],"container-title":["Practical Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/practneurol-2017-001738","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T18:07:53Z","timestamp":1757009273000},"score":1,"resource":{"primary":{"URL":"https:\/\/pn.bmj.com\/lookup\/doi\/10.1136\/practneurol-2017-001738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,1]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,3,27]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.1136\/practneurol-2017-001738"],"URL":"https:\/\/doi.org\/10.1136\/practneurol-2017-001738","relation":{},"ISSN":["1474-7758","1474-7766"],"issn-type":[{"value":"1474-7758","type":"print"},{"value":"1474-7766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,1]]}}}